Key facts
- It has raised $419.9M; the latest was Later Stage VC ($110.0M) in Apr 2026.
- Notable investors include Qiming Venture Partners, Beijing State-owned Capital Operation and Management, Qatar Investment Authority, RTW Investments, Vivo Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for OriCell Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for OriCell Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OriCell Therapeutics
Manufacturer of biopharmaceuticals intended to create innovative immunotherapies for the treatment of cancer. The company offers multiple cell therapy approaches, including autologous cellular engineering, dual-target targeting constructs, armored secreting cell therapies, and in vivo engineered cell therapeutics, enabling oncology patients worldwide to access rigorously developed treatments with the potential for durable clinical benefit.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Employees
- 150
- Website
- oricell.com/
- Ownership
- Privately Held (backing)
OriCell Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OriCell Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OriCell Therapeutics in its N-PORT filings yet. We sweep new filings monthly.